Composite dressings for improving granulation growth and reducing blistering by negative pressure therapy

By designing a composite dressing that combines negative pressure therapy and local treatment solution infusion, the problems of softening and insufficient granulation tissue growth in existing technologies have been solved, resulting in faster wound healing and more efficient tissue treatment.

CN121731067APending Publication Date: 2026-03-27SOLVENTUM INTELLECTUAL PROPERTIES CO
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202511921168.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2018-02-21
Filing Date
2018-06-05
Publication Date
2026-03-27

AI Technical Summary

Technical Problem

Existing negative pressure wound therapy and intravenous infusion therapy have problems with softening and insufficient granulation tissue growth in wound care, which affects the wound healing effect.

Method used

A composite dressing was designed, comprising a non-porous material membrane, a transparent material membrane, a foam layer, and a manifold layer. The structure and composition of the dressing were optimized to promote granulation tissue growth and reduce blistering through negative pressure therapy and local treatment solution infusion.

Benefits of technology

It increases the development speed of granulation tissue, reduces wound healing time, enhances wound cleaning, and provides a more efficient tissue treatment effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121731067A_ABST
    Figure CN121731067A_ABST
Patent Text Reader

Abstract

The application relates to composite dressings for improving granulation growth and reducing blistering by negative pressure therapy. Dressings for treating a tissue site with negative pressure are disclosed, which may include a dressing having at least three layers assembled in a stacked relationship. In one exemplary embodiment, the first membrane may include a non-porous material and a plurality of fluid confinement portions. A first manifold layer may be adjacent to the first film and may include a second transparent material film having bubbles and a manifold area. The first manifold layer may further include an aperture configured to allow fluid to pass through the second membrane. A second manifold layer may be adjacent to the first manifold layer and may include a foam having a contact area that is less than a manifold area of the first manifold layer.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the application filed on June 5, 2018, with application number 201880044016.9 and invention title "Composite dressing for improving granulation tissue growth and reducing blistering through negative pressure therapy".

[0002] Related applications This application claims the following benefits under 35 USC § 119(e): U.S. Provisional Patent Application Serial No. 62 / 633,438, filed February 21, 2018, entitled "Composite Dressing for Improved Granulation and Reduced Maceration with Negative-Pressure Treatment"; U.S. Provisional Patent Application Serial No. 62 / 623,325, filed January 29, 2018, entitled "Methods for Manufactured and Assembling Dual Material Tissue Interface for Negative-Pressure Therapy"; and U.S. Provisional Patent Application Serial No. 62 / 623,325, filed February 2, 2018, entitled "Customizable Composite Dressing for Improved Granulation and Reduced Maceration with Negative-Pressure Treatment". U.S. Provisional Patent Application Serial No. 62 / 625,704, entitled "Composite Dressings for Improved Granulation and Reduced Maceration with Negative-Pressure Treatment" filed January 11, 2018; U.S. Provisional Patent Application Serial No. 62 / 616,244, entitled "Composite Dressings for Improved Granulation and Reduced Maceration with Negative-Pressure Treatment" filed January 10, 2018; and Methods for Manufacturing and Assembling Dual Material Tissue Interface for Negative-Pressure Treatment filed January 10, 2018. U.S. Provisional Patent Application Serial No. 62 / 615,821, entitled "PEEL AND PLACE DRESSING FOR THICK EXUDATE AND INSTILLATION", filed January 4, 2018, and U.S. Provisional Patent Application Serial No. 62 / 613, entitled "PEEL AND PLACE DRESSING FOR THICK EXUDATE AND INSTILLATION",494. U.S. Provisional Patent Application Serial No. 62 / 592,950, filed November 30, 2017, entitled "MULTI-LAYER WOUND FILLER FOR EXTENDEDWEAR TIME"; U.S. Provisional Patent Application Serial No. 62 / 576,498, filed October 24, 2017, entitled "SYSTEMS, APPARATUSES, ANDMETHODS FOR NEGATIVE-PRESSURE TREATMENT WITH REDUCED TISSUE IN-GROWTH"; and U.S. Provisional Patent Application Serial No. 62 / 576,498, filed September 29, 2017, entitled "COMPOSITE DRESSINGS FOR IMPROVED GRANULATION ANDREDUCED MACERATION WITH NEGATIVE-PRESSURE". U.S. Provisional Patent Application Serial No. 62 / 565,754 entitled "Treatment", U.S. Provisional Patent Application Serial No. 62 / 516,540 entitled "Tissue Contact Interface", filed June 7, 2017; U.S. Provisional Patent Application Serial No. 62 / 516,550 entitled "Composite Dressings for Improved Granulation and Reduced Maceration with Negative-Pressure Treatment", filed June 7, 2017; and U.S. Provisional Patent Application Serial No. 62 / 516,550 entitled "Composite Dressings for Improved Granulation and Reduced Maceration with Negative-Pressure Treatment", filed June 7, 2017. The U.S. Provisional Patent Application Serial No. 62 / 516,566, entitled "TREATMENT", is incorporated herein by reference for all purposes. Technical Field

[0003] The invention set forth in the appended claims generally relates to tissue treatment systems, and more specifically, but not in a limited way, to dressings for tissue treatment using negative pressure, and methods of using dressings for tissue treatment using negative pressure. Background Technology

[0004] Clinical research and practice have shown that reducing pressure near tissue sites can promote and accelerate the growth of new tissue at those sites. This phenomenon has many applications, but it has proven particularly beneficial in wound treatment. Regardless of whether the wound is caused by trauma, surgery, or other reasons, proper wound care is crucial to the outcome. Using decompression to treat wounds or other tissues is commonly referred to as "negative pressure therapy," but it also has other names, including "negative pressure wound therapy," "decompression therapy," "vacuum therapy," "vacuum-assisted closure," and "local negative pressure." Negative pressure therapy can provide many benefits, including the migration of epithelial and subcutaneous tissues, improved blood flow, and micro-deformation of tissues at the wound site. These benefits can collectively enhance granulation tissue development and reduce healing time.

[0005] It is also widely accepted that cleaning tissue sites is highly beneficial for new tissue growth. For example, a liquid solution can be used to rinse a wound, or a liquid solution can be used to clean cavities for therapeutic purposes. These practices are often referred to as “irrigation” and “cleaning,” respectively. “Infusion” is another practice, which generally refers to the process of slowly introducing a fluid into a tissue site and retaining the fluid for a specified period of time before removing it. For example, infusing a local treatment solution into a wound bed can be combined with negative pressure therapy to further promote wound healing by diluting soluble contaminants in the wound bed and removing infectious material. As a result, the burden of soluble bacteria can be reduced, contaminants can be removed, and the wound can be cleaned.

[0006] While the clinical benefits of negative pressure therapy and / or infusion therapy are well known, improvements in therapy systems, components, and processes can benefit both healthcare providers and patients. Summary of the Invention

[0007] The appended claims set forth novel and useful systems, apparatus, and methods for treating tissues in a negative pressure therapy environment. Several illustrative embodiments are also provided to enable those skilled in the art to make and use the claimed subject matter.

[0008] For example, in some embodiments, a dressing for treating tissue sites with negative pressure may include a first membrane having a non-porous material; a first manifold layer adjacent to the first membrane and having a second transparent material membrane; and a second manifold layer adjacent to the first manifold layer. The first membrane may further include a plurality of fluid confinement portions. The second transparent material membrane of the first manifold layer may include bubbling and manifold areas and pores configured to allow fluid to pass through the second membrane. The second manifold layer may include foam with a contact area smaller than the manifold area.

[0009] In an additional embodiment, a dressing for treating tissue sites with negative pressure may include: a non-porous material membrane; a plurality of fluid-restricting portions through the membrane; a first manifold layer adjacent to the membrane; and a second manifold layer adjacent to the first manifold layer. The first manifold layer may include a transparent material and pores configured to allow fluid to pass through it. The second manifold layer may include a foam. The transparent material of the first manifold layer may be exposed around the foam.

[0010] In another embodiment, a dressing for treating tissue sites with negative pressure may include: a fluid control layer; a first manifold layer adjacent to the fluid control layer; and a second manifold layer adjacent to the first manifold layer. The first manifold layer may be configured to allow at least a portion of the tissue site to be seen through the first manifold layer. The first manifold layer may be visible around the second manifold layer.

[0011] In an additional embodiment, a dressing for treating tissue sites with negative pressure may include: a lower layer comprising a first at least partially transparent, liquid-impermeable material membrane; an upper layer positioned above the lower layer; and an intermediate layer located between the upper and lower layers. The first membrane may further include a plurality of fluid-restricting portions to allow fluid from the wound site to pass through the lower layer. The second membrane may include a second transparent material and a fluid port for engaging with a negative pressure source. The intermediate layer may include a foam, wherein the area of ​​the foam is smaller than the area of ​​the lower layer to allow visibility of the wound site beneath the upper and lower layers. In some embodiments, the area of ​​the foam may be less than 50% of the area of ​​the lower layer. In an additional embodiment, the dressing may further include a third membrane coupled to the lower layer and opposite to the upper layer. The third membrane may include a hydrophobic material having a plurality of pores. In some embodiments, the hydrophobic material may be a silicone material.

[0012] In an additional embodiment, a dressing for treating tissue sites with negative pressure may include: a first membrane comprising a non-porous material; a second membrane adjacent to the first membrane; and a manifold layer adjacent to the second membrane. The second membrane may include a transparent material and pores configured to allow fluid to pass through the transparent material. The manifold layer may include foam with a contact area smaller than that of the second membrane.

[0013] In an additional embodiment, a dressing for treating tissue sites with negative pressure may include: a first membrane comprising a non-porous material and a plurality of fluid-restricting portions; a second membrane adjacent to the first membrane; and a manifold layer adjacent to the second membrane. The second membrane may include a transparent material having bubbles. The second membrane may also include pores configured to allow fluid to pass through the transparent material. The manifold layer may include foam with a contact area smaller than that of the second membrane.

[0014] In an additional embodiment, a dressing for treating tissue sites with negative pressure may include: a first layer comprising a first non-porous material; a second layer adjacent to the first layer; and a third layer adjacent to the second layer. The second layer may include a transparent material having pores configured to allow fluid to pass through the second layer. The third layer may include a foam with a contact area smaller than the area of ​​the transparent material of the second layer.

[0015] In yet another embodiment, a method for treating a tissue site may include: positioning a dressing on the tissue site; checking the position of the dressing over an area of ​​the tissue site; and adjusting the position of the dressing. The dressing may include: a first membrane comprising a non-porous material and having a plurality of fluid-restricting portions; a first manifold layer adjacent to the first membrane; and a second manifold layer adjacent to the first manifold layer. The first manifold layer may include a second transparent material membrane having a manifold area including bubbles and pores. The second manifold layer may include foam with a contact area smaller than the manifold area. The step of checking the position of the dressing over an area of ​​the tissue site may include viewing the area of ​​the tissue site through a portion of the first membrane and the first manifold layer. The position of the dressing may be adjusted such that the manifold area of ​​the dressing substantially corresponds to the area of ​​the tissue site within the boundaries of the tissue site.

[0016] This application also provides the following items: 1. A dressing for treating tissue sites using negative pressure, said dressing comprising: A first membrane, the first membrane comprising a non-porous material and a plurality of fluid confinement portions; A first manifold layer adjacent to the first membrane, the first manifold layer including a second transparent material membrane, the second transparent material membrane having a manifold area including bubbles and pores, wherein the pores are configured to allow fluid to pass through the second membrane; and A second manifold layer adjacent to the first manifold layer, the second manifold layer comprising foam having a contact area smaller than the manifold area.

[0017] 2. The dressing as described in Item 1, wherein: The manifold area has a first shape; The contact area has a second shape; and The first shape is similar to the second shape.

[0018] 3. The dressing as described in Item 1, wherein: The manifold area has a first shape; The contact area has a second shape; The first shape is similar to the second shape; and The manifold area includes the boundary area surrounding the contact area.

[0019] 4. The dressing as described in Item 1, wherein the contact area includes at least three overhangs adjacent to the manifold area.

[0020] 5. The dressing as described in Item 1, wherein the contact area includes at least three radial overhangs adjacent to the manifold area.

[0021] 6. The dressing as described in Item 1, wherein the contact area includes: Central region; and At least three overhangs are connected to the central region.

[0022] 7. The dressing as described in Item 1, wherein the contact area includes: Central region; and At least three overhangs that are connected to the central region and extend to the edge of the manifold area.

[0023] 8. The dressing as described in Item 1, wherein the transparent material comprises polyurethane or polyethylene.

[0024] 9. The dressing as described in item 1, wherein the foam is a polymer foam.

[0025] 10. The dressing as described in Item 1, wherein the foam is a polyurethane ether foam.

[0026] 11. The dressing as described in Item 1, wherein the foam is an open-cell foam.

[0027] 12. The dressing as described in Item 1, wherein the foam is mesh-like.

[0028] 13. The dressing as described in Item 1, wherein the foam is a reticulated polymer foam.

[0029] 14. The dressing as described in Item 1, wherein the foam is a reticulated polyurethane ether foam.

[0030] 15. The dressing as described in Item 1, wherein the foam is mesh-like and has at least 90% free volume.

[0031] 16. The dressing as described in Item 1, wherein the foam is porous and its average pore size is in the range of 400 to 600 micrometers.

[0032] 17. The dressing as described in Item 1, wherein the thickness of the foam is less than 7 mm.

[0033] 18. The dressing as described in Item 1, wherein the thickness of the foam is in the range of 2 mm to 7 mm.

[0034] 19. The dressing as described in Item 1, wherein the foam is hydrophobic.

[0035] 20. The dressing as described in Item 1, wherein the bubbles are spaced about 2 mm apart.

[0036] 21. The dressing as described in Item 1, wherein the height of the blister is from about 0.5 mm to about 2 mm.

[0037] 22. The dressing as described in Item 1, wherein the width of the blister is from about 1 mm to about 3 mm.

[0038] 23. The dressing as described in Item 1, wherein the first membrane comprises a smooth surface texture.

[0039] 24. The dressing as described in Item 1, wherein the second manifold layer is substantially opaque.

[0040] 25. The dressing as described in Item 1, wherein: The bubbles are spaced approximately 2 millimeters apart; The height of the bubble is approximately 1.5 millimeters; and The diameter of the bubble is approximately 1.5 millimeters.

[0041] 26. A dressing for treating tissue sites using negative pressure, said dressing comprising: Non-porous material film layer; Multiple fluid confinement sections passing through the membrane layer; A first manifold layer adjacent to the membrane layer, the first manifold layer comprising a transparent material; Configured to allow fluid to pass through the orifice of the first manifold layer; and A second manifold layer adjacent to the first manifold layer, the second manifold layer comprising foam; In this embodiment, at least a portion of the transparent material is exposed outside one or more perimeter edges of the foam.

[0042] 27. The dressing as described in item 26, wherein: The first manifold layer has a periphery that defines the manifold area; The foam is a cylinder, and the cylinder has a surface that defines the surface area; and The surface area of ​​the foam is smaller than the area of ​​the manifold.

[0043] 28. The dressing as described in item 26, wherein the foam comprises radial leg portions.

[0044] 29. The dressing as described in item 26, wherein the foam comprises at least three radial legs.

[0045] 30. The dressing as described in item 26, wherein the foam comprises at least four radial legs.

[0046] 31. The dressing as described in item 26, wherein the foam comprises more than four radial legs.

[0047] 32. The dressing as described in item 26, wherein the foam has a star shape.

[0048] 33. The dressing as described in item 26, wherein, when viewed from the top of the dressing, the portion of the transparent material is exposed around the foam.

[0049] 34. A dressing for treating tissue sites using negative pressure, said dressing comprising: Fluid control layer; A first manifold layer adjacent to the fluid control layer, the first manifold layer being configured to allow at least a portion of the tissue site to be seen through the first manifold layer; and A second manifold layer connected to the first manifold layer; The first manifold layer is visible around the second manifold layer.

[0050] 35. A dressing for treating tissue sites using negative pressure, said dressing comprising: The lower layer includes a first at least partially transparent liquid-impermeable material membrane having a first side and a second side, and further includes a plurality of fluid confinement portions to allow fluid from the wound site to pass through the lower layer; An upper layer positioned above the lower layer, the upper layer comprising: A second transparent material film, the upper layer further including a fluid port for cooperating with a negative pressure source; and An intermediate layer located between the lower layer and the upper layer, the intermediate layer comprising foam, wherein the surface area of ​​the foam face is smaller than the surface area of ​​the second side face of the lower layer, to allow visibility of the wound site beneath the upper and lower layers.

[0051] 36. The dressing as described in item 35, wherein the second membrane includes protrusions.

[0052] 37. The dressing as described in item 35, wherein the second membrane includes spacers, wherein each spacer has a height of about 0.5 mm to about 2 mm.

[0053] 38. The dressing as described in item 35, wherein the surface area of ​​the foam side is less than 50% of the surface area of ​​the second side of the underlying layer.

[0054] 39. The dressing as described in item 35, wherein the upper layer extends beyond the perimeter of the lower layer.

[0055] 40. The dressing as described in item 35, wherein the upper layer further comprises an adhesive applied to a first surface of the upper layer.

[0056] 41. The dressing as described in item 35 further includes a third membrane attached to the lower layer and opposite to the upper layer, the third membrane comprising a hydrophobic material having a plurality of pores.

[0057] 42. The dressing as described in item 41, wherein the hydrophobic material is a gel.

[0058] 43. The dressing as described in item 41, wherein the hydrophobic material comprises silicone.

[0059] 44. A dressing for treating tissue sites using negative pressure, said dressing comprising: The first membrane includes non-porous materials; A second membrane adjacent to the first membrane, the second membrane comprising: A transparent material having a first side and a second side, wherein the first side and the second side each have a surface area, and Configured to allow fluid to pass through the pores in the transparent material; and A manifold layer adjacent to the second side surface of the second membrane, the manifold layer comprising foam having a surface area defined by the foam, the surface area being smaller than the surface area of ​​the second side surface of the second membrane.

[0060] 45. A dressing for treating tissue sites using negative pressure, said dressing comprising: A first membrane, the first membrane comprising a non-porous material and a plurality of fluid confinement portions; A second membrane adjacent to the first membrane, the second membrane comprising: Transparent materials with raised structures, and Configured to allow fluid to pass through the pores in the transparent material; and A manifold layer adjacent to the second membrane, the manifold layer comprising foam; The foam has a cross-section parallel to the second membrane, and the area of ​​the cross-section is smaller than the area of ​​the side surface of the second membrane.

[0061] 46. ​​A dressing for treating tissue sites using negative pressure, said dressing comprising: The first layer comprises a first non-porous material and has a first side surface and a second side surface; A second layer adjacent to the second side of the first layer, the second layer comprising a transparent material having the first side and the second side, and further comprising a hole configured to allow fluid to pass through the second layer; and A third layer having a first side and a second side parallel to the first side, wherein the first side of the third layer is positioned adjacent to the second side of the second layer, and the surface areas of the first side and the second side of the third layer are each smaller than the surface area of ​​the second side of the second layer. The third layer includes foam.

[0062] 47. A method for treating a tissue site, comprising: The dressing is positioned on the tissue site, the dressing comprising: A first membrane, the first membrane comprising a non-porous material and a plurality of fluid confinement portions; A first manifold layer adjacent to the first membrane, the first manifold layer including a second transparent material membrane, the second transparent material membrane having a manifold area including bubbles and pores; and A second manifold layer adjacent to the first manifold layer, the second manifold layer comprising foam having a contact area smaller than the manifold area; The position of the dressing on the area of ​​the tissue site is examined by viewing the area of ​​the tissue site through a portion of the first membrane and the first manifold layer; and The position of the dressing is adjusted such that the manifold area of ​​the dressing substantially corresponds to the area of ​​the tissue site within the boundary of the tissue site.

[0063] 48. The method of item 47, further comprising applying negative pressure to the dressing.

[0064] 49. As described in Project 47, wherein: The manifold area has a first shape; The contact area has a second shape; and The first shape is similar to the second shape.

[0065] 50. The method of item 47, wherein the manifold area includes the boundary area surrounding the contact area.

[0066] 51. The method of item 47, wherein the contact area includes at least three overhangs adjacent to the manifold area.

[0067] 52. The method of item 47, wherein the transparent material comprises polyurethane or polyethylene.

[0068] 53. The method as described in item 47, wherein the thickness of the foam is in the range of 4 mm to 10 mm.

[0069] 54. The method as described in item 47, wherein the height of the bubble is from about 0.5 mm to about 2 mm.

[0070] 55. Systems, apparatus and methods substantially as described herein.

[0071] The purpose, advantages, and preferred methods of making and using the claimed subject matter can be best understood by referring to the accompanying drawings and the following detailed description of illustrative embodiments. Attached Figure Description

[0072] Figure 1 This is a functional block diagram of an exemplary embodiment of a therapeutic system that can provide tissue therapy according to this specification; Figure 2 This is an assembled view of an example of a dressing, showing how it can be combined with... Figure 1 Additional details associated with some exemplary embodiments of the therapeutic system; Figure 3 It is possible to be with Figure 2 A schematic diagram of an exemplary configuration of a fluid confinement portion in an associated layer of some embodiments of the dressing; Figure 4 This is a schematic diagram of an exemplary configuration of a hole in another layer, demonstrating that it can be used with... Figure 2 Additional details associated with some embodiments of the dressing; Figure 5 yes Figure 4 Exemplary layers superimposed on Figure 3 A schematic diagram on an exemplary layer; Figure 6 It is possible to be with Figure 2 A perspective view of an exemplary configuration of a bubble in another layer associated with some embodiments of the dressing; Figure 7 It is a cross-sectional view, showing what can be compared with... Figure 6 Additional details associated with some embodiments of the layer; Figure 8This is another illustration of a dressing, showing how it can be used with... Figure 1 Additional details associated with some exemplary embodiments of the therapeutic system; Figure 9 This is another illustration of a dressing, showing how it can be used with... Figure 1 Additional details associated with some exemplary embodiments of the therapeutic system; and Figure 10 This is an assembled view of another example of dressing, showing how it can be used with... Figure 1 Additional details associated with some exemplary embodiments of the therapeutic system. Detailed Implementation

[0073] The following description of exemplary embodiments provides information that enables those skilled in the art to make and use the subject matter set forth in the appended claims, but certain details already well known in the art may be omitted. Therefore, the following detailed description should be understood as illustrative rather than restrictive.

[0074] This document may also describe the exemplary embodiments with reference to the spatial relationships or spatial orientations of the different elements depicted in the accompanying drawings. Generally, such relationships or orientations assume a reference frame consistent with or relative to the patient in the position to be treated. However, those skilled in the art should recognize that this reference frame is merely a descriptive and appropriate measure, and not a strict specification.

[0075] Figure 1 This is a simplified functional block diagram of an exemplary embodiment of a therapy system 100 that can provide negative pressure therapy and local therapeutic solution infusion according to this specification.

[0076] In this context, the term "tissue site" broadly refers to a wound, defect, or other therapeutic target located on or within tissue, including but not limited to surface wounds, bone tissue, adipose tissue, muscle tissue, nerve tissue, skin tissue, vascular tissue, connective tissue, cartilage, tendons, or ligaments. The term "tissue site" can also refer to any area of ​​tissue that is not necessarily injured or defective, but rather an area in which it may be desirable to increase or facilitate the growth of additional tissue. For example, negative pressure can be applied to a tissue site to encourage the growth of additional tissue that can be harvested and transplanted. As used herein, a surface wound is an injury to the external surface of the body, such as damage or injury to the epidermis, dermis, and / or subcutaneous layer. For example, a surface wound can include an ulcer or a closed incision. As used herein, a surface wound does not include wounds within the abdominal cavity. Wounds can include, for example, chronic, acute, traumatic, subacute, and laceration wounds, partial skin burns, ulcers (such as diabetic ulcers, pressure ulcers, or venous insufficiency ulcers), flaps, and grafts.

[0077] The therapeutic system 100 may include a negative pressure supply source and may include or be configured to be coupled to a distribution component (such as a dressing). Generally, a distribution component can refer to any supplementary or auxiliary component configured to be fluidly coupled to the negative pressure supply source in a fluid path between the negative pressure supply source and the tissue site. The distribution component is preferably detachable and may be disposable, reusable, or recyclable. For example, a dressing 102 may be fluidly coupled to a negative pressure source 104, such as… Figure 1 As shown. In some embodiments, the dressing may include a cover, an tissue interface, or both. Dressing 102 may include, for example, a cover 106 and an tissue interface 108. A regulator or controller (such as controller 110) may also be coupled to the negative pressure source 104.

[0078] In some embodiments, the dressing interface may facilitate the attachment of the negative pressure source 104 to the dressing 102. For example, such a dressing interface may be a SENSAT.RAC™ pad available from Kinetic Concepts, Inc., San Antonio, Texas. The therapy system 100 may optionally include a fluid container, such as container 112, attached to the dressing 102 and the negative pressure source 104.

[0079] The therapeutic system 100 may also include an infusion solution source. For example, the solution source 114 may be fluidly coupled to the dressing 102, such as... Figure 1 As illustrated in the exemplary embodiments. In some embodiments, the solution source 114 may be fluidly connected to a positive pressure source, such as positive pressure source 116, or may be fluidly connected to a negative pressure source 104. A regulator, such as an infusion regulator 118, may also be fluidly connected to the solution source 114 and the dressing 102. In some embodiments, the infusion regulator 118 may also be fluidly connected to the negative pressure source 104 via the dressing 102, such as... Figure 1 The examples shown are as follows.

[0080] Additionally, the therapy system 100 may include sensors for measuring operating parameters and providing feedback signals indicative of these parameters to the controller 110. For example... Figure 1 As shown, for example, the therapy system 100 may include a first sensor 120 and a second sensor 122 coupled to the controller 110. The first sensor 120 may also be coupled to or configured to be coupled to the distribution unit and the negative pressure source 104.

[0081] Components can be fluidly connected to each other to provide a path for the transfer of fluids (i.e., liquids and / or gases) between these components. For example, these components can be fluidly connected by fluid conductors (such as tubes). As used herein, "tube" broadly includes pipes, conduits, hoses, tubing, or other structures having one or more lumens adapted to transfer fluid between two ends. Typically, tubes are slender cylindrical structures with a degree of flexibility, but their geometry and rigidity can vary. In some embodiments, components can also be connected by physical proximity, integral with a single structure, or formed from the same material. Furthermore, some fluid conductors can be molded into other components or otherwise integrally combined with other components. In some cases, the connection can also include mechanical, thermal, electrical, or chemical connections (such as chemical bonds). For example, in some embodiments, a tube can mechanically and fluidly connect dressing 102 to container 112.

[0082] In general, the components of the therapy system 100 can be connected directly or indirectly. For example, the negative pressure source 104 can be directly connected to the controller 110 and indirectly connected to the dressing 102 via the container 112.

[0083] A negative pressure supply source, such as negative pressure source 104, can be an air reservoir under negative pressure, or a manually or electrically driven device that can reduce the pressure in a sealed volume, such as a vacuum pump, a suction pump, a wall-mounted suction port used in many healthcare facilities, or a micropump. The negative pressure supply source can be housed within or combined with other components, such as sensors, processing units, alarm indicators, memory, databases, software, display devices, or further user interfaces that facilitate therapy. For example, in some embodiments, negative pressure source 104 can be combined with controller 110 and other components to form a therapy unit. The negative pressure supply source may also have one or more supply ports configured to facilitate connection and disconnection of the negative pressure supply source to one or more distribution components.

[0084] The tissue interface 108 can be generally adapted to contact a tissue site. The tissue interface 108 can be in partial or complete contact with the tissue site. If the tissue site is, for example, a wound, the tissue interface 108 can partially or completely fill the wound, or it can be placed on the wound. The tissue interface 108 can take many forms and can have various sizes, shapes, or thicknesses, depending on various factors such as the type of treatment being performed or the nature and size of the tissue site. For example, the size and shape of the tissue interface 108 can be adapted to the contours of deep and irregularly shaped tissue sites. Furthermore, any or all surfaces of the tissue interface 108 can have protrusions or uneven, rough, or jagged contours that can induce strain and stress in the tissue site, which can promote granulation tissue growth at the tissue site.

[0085] In some embodiments, tissue interface 108 may include a manifold. In this context, a "manifold" generally includes any material or structure suitable for providing multiple paths for collecting fluid at a tissue site under pressure or distributing fluid at a tissue site. For example, a manifold may be adapted to receive negative pressure from a source and distribute that negative pressure at a tissue site through multiple orifices, which can have the effect of collecting fluid from the tissue site and drawing the fluid toward the source. In some embodiments, the fluid paths may be reversed, or auxiliary fluid paths may be provided to facilitate fluid delivery to the tissue site.

[0086] Tissue interface 108 may include one or both of hydrophobic and hydrophilic materials. In instances where tissue interface 108 is hydrophilic, it may also wick fluid from the tissue site while continuing to distribute negative pressure to the tissue site. The wicking properties of tissue interface 108 may draw fluid from the tissue site via capillary flow or other wicking mechanisms. An example of a hydrophilic foam is a polyvinyl alcohol open-cell foam, such as VACWHITEFOAM™ dressings available from Kinetic Concepts, Inc., San Antonio, Texas. Other hydrophilic foams may include hydrophilic foams made of polyether. Other foams that may exhibit hydrophilic characteristics include hydrophobic foams that have been treated or coated to provide hydrophilicity.

[0087] When the pressure within the sealed treatment environment is reduced, the tissue interface 108 can further promote granulation tissue formation at the tissue site. For example, any or all surfaces of the tissue interface 108 may have an uneven, rough, or irregular profile, which can induce microstrain and stress at the tissue site if negative pressure is applied through the tissue interface 108.

[0088] In some embodiments, the tissue interface 108 may also be composed of one or more bioabsorbable materials. Suitable bioabsorbable materials may include, but are not limited to, polymeric blends of polylactic acid (PLA) and polyglycolic acid (PGA). The polymeric blends may also include, but are not limited to, polycarbonate, polyfuric acid ester, and caprolactone.

[0089] In some embodiments, the cover 106 can provide a bacterial barrier and protection against physical trauma. The cover 106 may also be made of a material that reduces evaporation loss and provides a fluid seal between two components or environments, such as a treatment environment and a local external environment. The cover 106 may be, for example, an elastomeric membrane or film that can provide a seal sufficient to maintain negative pressure at the tissue site for a given negative pressure source. In some applications, the cover 106 may have a high moisture vapor transmission rate (MVTR). For example, in some embodiments, the MVTR may be at least 250 g / m² per 24 hours, measured at 38°C and 10% relative humidity (RH) using the upright cup technique according to the ASTM E96 / E96M upright cup method. In some embodiments, an MVTR of up to 5,000 g / m² per 24 hours can provide effective breathability and mechanical properties. In some exemplary embodiments, the cover 106 may be a water vapor permeable but liquid impermeable polymer cover, such as a polyurethane membrane. Such covers typically have a thickness in the range of 25 to 50 micrometers. For permeable materials, the permeability should generally be low enough to maintain the desired negative pressure.

[0090] An attachment device can be used to attach the cover 106 to an attachment surface, such as an undamaged epidermis, gasket, or another cover. The attachment device can take many forms. For example, the attachment device can be a medically acceptable pressure-sensitive adhesive that extends around the periphery of the sealing member, a portion of the sealing member, or the entire sealing member. In some embodiments, for example, some or all of the cover 106 can be coated with an acrylic adhesive having a coating weight between 25 and 65 grams per square meter (gsm). In some embodiments, a thicker adhesive or adhesive combination can be applied to improve sealing and reduce leakage. Other exemplary embodiments of the attachment device may include double-sided tape, paste, hydrocolloid, hydrogel, silicone gel, or organic gel.

[0091] A controller, such as controller 110, may be a microprocessor or computer programmed to operate one or more components of the therapy system 100 (e.g., negative pressure source 104). In some embodiments, controller 110 may be a microcontroller that typically includes an integrated circuit including a processor core and memory programmed to directly or indirectly control one or more operating parameters of the therapy system 100. For example, operating parameters may include power applied to negative pressure source 104, pressure generated by negative pressure source 104, or pressure distributed to tissue interface 108. Controller 110 is also preferably configured to receive one or more input signals, such as feedback signals, and is programmed to modify one or more operating parameters based on the input signals.

[0092] Sensors, such as first sensor 120 and second sensor 122, are generally considered in the art to be any device operable to detect or measure a physical phenomenon or property, and typically provide a signal indicating the detected or measured phenomenon or property. For example, first sensor 120 and second sensor 122 may be configured to measure one or more operating parameters of the therapeutic system 100. In some embodiments, first sensor 120 may be a transducer configured to measure pressure in a pneumatic passage and convert the measurement into a signal indicating the measured pressure. In some embodiments, for example, first sensor 120 may be a piezoresistive strain gauge. In some embodiments, second sensor 122 may optionally measure operating parameters of the negative pressure source 104, such as voltage or current. Preferably, the signals from first sensor 120 and second sensor 122 are suitable as input signals to controller 110, but in some embodiments, some signal conditioning may be appropriate. For example, the signal may need to be filtered or amplified before being processed by controller 110. Typically, the signal is an electrical signal, but may be represented in other forms, such as an optical signal.

[0093] Container 112 is representative of containers, canisters, pouches, or other storage components that can be used to manage exudates and other fluids aspirated from tissue sites. In many environments, rigid containers may be preferred or necessary for the collection, storage, and disposal of fluids. In other environments, fluids can be properly disposed of without the need for rigid container storage, and reusable containers can reduce waste and costs associated with negative pressure therapy.

[0094] Solution source 114 may also represent a container, canister, pouch, bag, or other storage component that can provide a solution for infusion therapy. The composition of the solution may vary depending on the prescribed therapy, but examples of solutions suitable for certain prescriptions include hypochlorite-based solutions, silver nitrate (0.5%), sulfur-based solutions, biguanide, cation solutions, and isotonic solutions.

[0095] During operation, the tissue interface 108 can be placed within, above, on, or otherwise close to the tissue site. A cap 106 can be placed over the tissue interface 108 and sealed to an attachment surface near the tissue site. For example, the cap 106 can seal to undamaged epidermis surrounding the tissue site. Thus, the dressing 102 can provide a sealed therapeutic environment substantially isolated from the external environment close to the tissue site, and the negative pressure source 104 can reduce pressure within the sealed therapeutic environment. The negative pressure applied to the tissue site within the sealed therapeutic environment through the tissue interface 108 can induce macro- and micro-strains in the tissue site and remove exudates and other fluids from the tissue site, which can be collected in the container 112.

[0096] The fluid dynamics of using a negative pressure source to reduce pressure in another component or location (such as within a sealed treatment environment) can be mathematically complex. However, the basic principles of fluid dynamics applicable to negative pressure therapy and infusion are generally well known to those skilled in the art, and the process of reducing pressure can be illustratively described herein as, for example, “delivering,” “distributing,” or “generating” negative pressure.

[0097] Generally, exudates and other fluids flow along the fluid path toward lower pressure. Therefore, the term "downstream" typically refers to a location relatively closer to a negative pressure source or further away from a positive pressure source within the fluid path. Conversely, the term "upstream" refers to a location relatively further away from a negative pressure source or closer to a positive pressure source. Similarly, it may be appropriate to describe certain features in this frame of reference according to the fluid's "inlet" or "outlet." This orientation is generally assumed to be for describing the different features and components described herein. However, in some applications, the fluid path can be reversed (e.g., by replacing the negative pressure source with a positive pressure source), and this descriptive convention should not be construed as restrictive.

[0098] "Negative pressure" generally refers to pressure less than the local ambient pressure, which is, for example, the ambient pressure in a local environment outside the sealed treatment environment provided by dressing 102. In many cases, the local ambient pressure can also be atmospheric pressure at the location of the tissue site. Alternatively, the pressure can be less than the hydrostatic pressure associated with the tissue at the tissue site. Unless otherwise stated, the pressure values ​​stated herein are gauge pressures. Similarly, an increase in negative pressure generally refers to a decrease in absolute pressure, and a decrease in negative pressure generally refers to an increase in absolute pressure. Although the amount and nature of the negative pressure applied to the tissue site can vary depending on treatment needs, the pressure is generally a low vacuum, also commonly referred to as a rough vacuum, between -5 mm Hg (-667 Pa) and -500 mm Hg (-66.7 kPa). Common treatment ranges are between -75 mm Hg (-9.9 kPa) and -300 mm Hg (-39.9 kPa).

[0099] Figure 2 yes Figure 1 An assembled view of an instance of dressing 102 shows additional details that can be associated with some embodiments in which tissue interface 108 may include more than one layer. Figure 2 In an example, the tissue interface 108 includes a first layer 205, a second layer 210, a third layer 220, and a fourth layer 225. In some embodiments, the first layer 205 may be arranged adjacent to the second layer 210, and the third layer 220 may be arranged adjacent to the second layer 210 and opposite to the first layer 205. Additionally, the fourth layer 225 may be arranged adjacent to the third layer 220 and opposite to the second layer 210. For example, the first layer 205, second layer 210, third layer 220, and fourth layer 225 may be stacked such that the first layer 205 contacts the second layer 210, the second layer 210 contacts the first layer 205 and the third layer 220, and the third layer 220 contacts the second layer 210 and the fourth layer 225. In some embodiments, one or more of the first layer 205, second layer 210, third layer 220, and fourth layer 225 may also be bonded to adjacent layers. Although the entire dressing 102 (including the layers of the tissue interface 108) is in Figure 2 While the dressing 102 is shown as having a generally square shape, the dressing 102 and its contained layers can be any number of different shapes based on the specific anatomical needs of the tissue site. For example, the dressing 102 and its contained layers can be square, rectangular, oval, circular, hexagonal, or other shapes. Additionally, the dressing 102 can further include three-dimensional forms that can be welded and shaped to address the needs of specific types of tissue sites, such as breast or post-amputation wounds.

[0100] The first layer 205 may be a sealing layer and may have a substantially flat surface. This sealing layer comprises or is substantially composed of a soft, viscous material suitable for providing a fluid seal with the tissue site. For example, the first layer 205 may include, but is not limited to: silicone gel, soft silicone, hydrocolloid, hydrogel, polyurethane gel, polyolefin gel, hydrogenated styrene copolymer gel, foam gel, soft closed-cell foam (such as polyurethane and polyolefin coated with an adhesive), polyurethane, polyolefin, or hydrogenated styrene copolymer. In some embodiments, the first layer 205 may be in the form of a film and have a thickness between about 200 micrometers (μm) and about 1000 micrometers (μm). In some embodiments, the first layer 205 may have a hardness between about 5 Shore A00 and about 80 Shore A00. Additionally, the first layer 205 may be composed of a hydrophobic or hydrophilic material.

[0101] In some embodiments, the first layer 205 may be a hydrophobic coating material. For example, the first layer 205 may be formed by coating a spacer material (such as a woven, nonwoven, molded, or extruded mesh) with a hydrophobic material. For example, the hydrophobic material used for coating may be soft silicone.

[0102] The first layer 205 may have a periphery 230 surrounding or surrounding the inner portion 235, and holes 240 arranged through the periphery 230 and the inner portion 235. In some instances, the inner portion 235 may correspond to the surface area of ​​the second layer 210. The first layer 205 may also have corners 245 and edges 250. These corners 245 and edges 250 may be part of the periphery 230. The first layer 205 may have an inner boundary 255 surrounding the inner portion 235, which is arranged between the inner portion 235 and the periphery 230. The inner boundary 255 may be substantially without holes 240, as... Figure 2 As shown in the examples. In some instances, such as Figure 2 As shown, the interior portion 235 can be symmetrical and centrally arranged in the first layer 205.

[0103] The aperture 240 can be formed by cutting, by applying localized RF or ultrasonic energy, or by other suitable techniques for forming openings. The aperture 240 can have a uniform distribution pattern or can be randomly distributed on the first layer 205. The apertures 240 in the first layer 205 can have a variety of shapes, including, for example, circular, square, star-shaped, oval, polygonal, slit, complex curve, straight line, triangle, or some combination of such shapes.

[0104] Each hole 240 may have uniform or similar geometric characteristics. For example, in some embodiments, each hole 240 may be a circular hole having substantially the same diameter. In some embodiments, the diameter of each hole 240 may be between about 1 mm and about 50 mm. In other embodiments, the diameter of each hole 240 may be between about 1 mm and about 20 mm.

[0105] In other embodiments, the geometry of the aperture 240 can be varied. For example, the diameter of the aperture 240 can vary depending on its position within the first layer 205, such as... Figure 2 As shown. In some embodiments, the diameter of the hole 240 located in the periphery 230 of the first layer 205 may be larger than the diameter of the hole 240 located in the inner portion 235 of the first layer 205. For example, in some embodiments, the diameter of the hole 240 arranged in the periphery 230 may be between about 9.8 mm and about 10.2 mm. In some embodiments, the diameter of the hole 240 arranged in the corner 245 may be between about 7.75 mm and about 8.75 mm. In some embodiments, the diameter of the hole 240 arranged in the inner portion 235 may be between about 1.8 mm and about 2.2 mm.

[0106] At least one hole 240 in the periphery 230 of the first layer 205 can be positioned at an edge 250 of the periphery 230 and can have an internal cutout that opens or exposes at the edge 250, the internal cutout being in fluid communication with these edges 250 in a lateral direction. The lateral direction can refer to a direction toward the edge 250 and in the same plane as the first layer 205. Figure 2 As shown in the example, the holes 240 in the periphery 230 can be positioned near or at the edges 250 and are in fluid communication with these edges 250 in the lateral direction. The holes 240 positioned near or at the edges 250 can be spaced substantially equidistantly around the periphery 230, such as... Figure 2 As shown in the example. Alternatively, the spacing of the holes 240 near or at edge 250 can be irregular.

[0107] The second layer 210 may include or be substantially composed of means for controlling or managing fluid flow. In some embodiments, the second layer 210 may include or be substantially composed of a liquid-impermeable elastomeric material. For example, the second layer 210 may include or be substantially composed of a non-porous polymer membrane. In some embodiments, the second layer 210 may also have a smooth or matte surface texture. A gloss or bright finish better than or equal to SPI (Plastics Industry Association) B3 grade may be particularly advantageous for certain applications. In some embodiments, variations in surface height may be limited to acceptable tolerances. For example, the surface of the second layer may have a substantially flat surface with height variations limited to 0.2 mm over one centimeter.

[0108] In some embodiments, the second layer 210 may be hydrophobic. In some embodiments, the hydrophobicity of the second layer 210 may vary, but the contact angle with water may be at least 90 degrees. In some embodiments, the contact angle of the second layer 210 with water may not exceed 150 degrees. For example, in some embodiments, the contact angle of the second layer 210 may be in the range of at least 90 degrees to about 120 degrees, or in the range of at least 120 degrees to 150 degrees. Any standard device can be used to measure the water contact angle. While a manual goniometer can be used to visually estimate the contact angle, contact angle measuring instruments typically include an integrated system, which in particular includes a leveling platform, a liquid dropper (e.g., a syringe), a camera, and software designed to calculate the contact angle more accurately and precisely. Non-limiting examples of such integrated systems may include the FTÅ125, FTÅ200, FTÅ2000, and FTÅ4000 systems, all commercially available from First Ten Angstroms, Inc., Portsmouth, VA; and the DTA25, DTA30, and DTA100 systems, all commercially available from Kruss GmbH, Hamburg, Germany. Unless otherwise stated, the water contact angles described herein were measured using deionized and distilled water on a level sample surface with seated drops added from a height of no more than 5 cm in air at 20°C–25°C and 20%–50% relative humidity. The contact angles reported herein represent the average of 5 to 9 measurements, discarding both the maximum and minimum measured values. The hydrophobicity of the second layer 210 can be further enhanced by a hydrophobic coating of other materials (such as silicone and fluorocarbons), either by liquid coating or plasma coating.

[0109] The second layer 210 can also be adapted to be welded to other layers. For example, the second layer 210 can be adapted to be welded to other film layers using heat, radio frequency (RF) welding, or other heat-generating methods (such as ultrasonic welding). RF welding is particularly suitable for highly polar materials such as polyurethane, polyamide, polyester, and acrylate. Sacrificial polarity interfaces can be used to facilitate RF welding of less polar film materials such as polyethylene.

[0110] The area density of the second layer 210 can vary depending on the prescribed therapy or application. In some embodiments, an area density of less than 40 grams per square meter may be suitable, and an area density of about 20 to 30 grams per square meter may be particularly advantageous for certain applications.

[0111] In some embodiments, for example, the second layer 210 may comprise, or be substantially composed of, a hydrophobic polymer, such as a polyethylene film. The simple and inert structure of polyethylene can provide a surface that interacts little (if any) with biological tissues and fluids, thus providing a surface that can facilitate free flow of liquids and low adhesion, which can be particularly advantageous for many applications. Other suitable polymer films include polyurethanes, acrylic compounds, polyolefins (e.g., cycloolefin copolymers), polyacetates, polyamides, polyesters, copolyesters, PEBAX block copolymers, thermoplastic elastomers, thermoplastic vulcanizates, polyethers, polyvinyl alcohol, polypropylene, polymethylpentene, polycarbonate, styrene, silicone, fluoropolymers, and acetates. Thicknesses between 20 micrometers and 100 micrometers are suitable for many applications. The film can be transparent, colored, or printed. Suitable highly polar films laminated onto polyethylene films include polyamides, copolyesters, ionomers, and acrylic compounds. To aid adhesion between the polyethylene and the polar film, a bonding layer, such as ethylene vinyl acetate or modified polyurethane, can be used. Methyl acrylate (EMA) films can also have hydrophobic and weldable properties suitable for certain configurations.

[0112] As in Figure 2 As shown in the examples, the second layer 210 may have one or more fluid confinement portions 260, which may be uniformly or randomly distributed on the second layer 210. The fluid confinement portions 260 may be bidirectional and pressure-responsive. For example, each fluid confinement portion 260 may generally include or be substantially composed of an elastic channel through the second layer 210, which is typically unstrained to significantly reduce fluid flow and may expand or open in response to a pressure gradient. In some embodiments, the fluid confinement portion 260 may include or be substantially composed of a perforation in the second layer 210. The perforation may be formed by removing material from the second layer 210. For example, in some embodiments, the perforation may be formed by cutting through the second layer 210, which may also deform the edges of the perforation. Where there is no pressure gradient across the perforation, the channel may be small enough to form a seal or fluid confinement, which may significantly reduce or prevent fluid flow. Alternatively or additionally, one or more fluid confinement portions 260 may be elastomeric valves that are normally closed when unstrained to significantly prevent fluid flow and may open in response to a pressure gradient. The openings in the second layer 210 can be valves suitable for some applications. The openings can also be formed by removing material from the second layer 210, but the amount of material removed and the size of the resulting opening can be much larger than the order of a perforation, and an edge without deformation can be obtained. Alternatively, in some embodiments, perforations can be formed by mechanically slitting the membrane material of the second layer 210, followed by controlled uniaxial and / or biaxial stretching.

[0113] For example, some embodiments of the fluid restrictor 260 may include one or more slits, slots, or combinations of slits and slots in the second layer 210, or substantially consist of them. In some instances, the fluid restrictor 260 may include, or consist of, a linear slot having a length of less than 4 mm and a width of less than 1 mm. In some embodiments, the length may be at least 2 mm and the width may be at least 0.4 mm. A length of about 3 mm and a width of about 0.5 mm may be particularly suitable for many applications, and a tolerance of about 0.1 mm may also be acceptable. For example, such dimensions and tolerances can be achieved by laser cutting, ultrasound, or other heating means. The linear slits or slots may be spaced about 2 to 4 mm apart along their length. Such a configuration of slots can be used as an imperfect valve, which significantly reduces fluid flow in a normally closed or idle state. For example, such slots may form a flow restrictor rather than being completely closed or sealed. The slots may expand or open wider in response to a pressure gradient to allow increased fluid flow.

[0114] The third layer 220 generally comprises or is substantially composed of a manifold or manifold area that provides means for collecting fluid on the tissue interface 108 under pressure or for distributing fluid on the tissue interface. For example, the third layer 220 may be adapted to receive negative pressure from a source and distribute the negative pressure on the tissue interface 108 through a plurality of orifices, which may have the effect of collecting fluid from the tissue site and drawing the fluid toward the source. In some embodiments, the fluid path may be reversed, or an auxiliary fluid path may be provided to facilitate the delivery of fluid, for example, from an infusion solution source, to the tissue interface 108.

[0115] In some embodiments, the third layer 220 may comprise, or be substantially composed of, a fluid-impermeable material membrane with bubbles. In some embodiments, the third layer 220 may comprise a transparent material membrane. Polyurethane and polyethylene are examples of fluid-impermeable materials suitable for some applications of the third layer 220. In some embodiments, bubbles may comprise raised structures, protrusions, spacers, or bulges. For example, the third layer 220 may comprise bubbles in the form of bubbles 270, which may extend above or below a reference plane of the third layer 220. Each bubble 270 may contain an empty cavity that can open to the surrounding environment. For example, multiple portions of the fluid-impermeable material membrane forming the third layer 220 may be shaped or formed to include bubbles 270. In some embodiments, bubbles 270 may be in the form of small regions of the membrane of the third layer 220 that form a vacuum. In some embodiments, each individual bubble in the bubbles 270 may be arched or hemispherical. Alternatively or concurrently, the bubble 270 may take the form of a raised structure with different shapes (e.g., generally conical, cylindrical, tubular with flat or hemispherical ends, or spherical). In some embodiments, the third layer 220 may be positioned in the tissue interface 108 such that the bubble 270 protrudes toward or towards the second layer 210. The pitch and spacing of the bubbles 270 may vary on the surface of the third layer 220. For example, the bubbles 270 may be spaced further apart in the central region of the third layer 220. The third layer 220 may further include pores 275 to allow fluid to pass through the membrane. The bubbles 270 may assist in enabling the third layer 220 to be used as a core manifold layer of the tissue interface 108. The surface area of ​​the third layer 220 (including the bubbles 270 and / or pores 275) may define the manifold area of ​​the third layer 220 and the tissue interface 108.

[0116] In some additional embodiments, the third layer 220 may include air bubbles in the form of air cavities, which may be open or closed. For example, the air bubbles may include closed pores, i.e., they may be in the form of sealed air cavities. Alternatively or additionally, the third layer 220 may also include ridges, grooves, or other structural features that are rigid enough to maintain its shape and form when used as part of the tissue interface 108.

[0117] The thickness of the third layer 220 can also be varied according to the needs of the prescribed therapy. For example, the thickness of the third layer 220 can be reduced to alleviate stress on other layers and reduce stretching on surrounding tissues. The thickness of the third layer 220 may also affect its compliance. In some embodiments, the third layer 220 may comprise a membrane with a thickness ranging from about 20 to 500 micrometers. For example, the third layer 220 may comprise a membrane with a thickness of approximately 250 micrometers having bubbles 270 with a diameter between 0.5 mm and 2.0 mm.

[0118] The fourth layer 225 may also include a manifold or manifold layer or consist substantially of it. For example, the fourth layer 225 may be adapted to receive negative pressure from a source and distribute the negative pressure on the tissue interface 108 through a plurality of orifices, which may have the effect of collecting fluid from the tissue site and drawing the fluid toward the source.

[0119] In some illustrative embodiments, the fourth layer 225 may include multiple interconnected pathways to improve fluid distribution or collection. In some embodiments, the fourth layer 225 may comprise or be substantially composed of a porous material with interconnected fluid pathways. For example, honeycomb foams, open-cell foams, mesh foams, porous tissue aggregates, and other porous materials such as gauze or felt pads typically include pores, edges, and / or walls adapted to form interconnected fluid channels. Liquids, gels, and other foams may also include or be cured to include pores and fluid pathways. In some embodiments, the fourth layer 225 may additionally or alternatively include protrusions forming interconnected fluid pathways. For example, the fourth layer 225 may be molded to provide surface protrusions defining interconnected fluid pathways. Any or all surfaces of the fourth layer 225 may have non-uniform, rough, or irregular profiles.

[0120] In some embodiments, the fourth layer 225 may comprise or be substantially composed of a mesh foam, the pore size and free volume of which may be varied as required by the prescribed therapy. For example, a mesh foam having at least 90% free volume may be suitable for many therapeutic applications, and foam with an average pore size in the range of 400 to 600 micrometers (40 to 50 pores per inch) may be particularly suitable for certain types of therapy. The tensile strength of the fourth layer 225 may also be varied as required by the prescribed therapy. For example, the tensile strength of the foam may be increased for instilling a topical treatment solution. The 25% compressive load deflection of the fourth layer 225 may be at least 0.35 psi, and the 65% compressive load deflection may be at least 0.43 psi. In some embodiments, the tensile strength of the fourth layer 225 may be at least 10 psi. The fourth layer 225 may have a tear strength of at least 2.5 psi. In some embodiments, the first layer 225 may be a foam composed of a polyol (such as a polyester or polyether), an isocyanate (such as toluene diisocyanate), and a polymerization modifier (such as an amine or a tin compound). In a non-limiting example, the fourth layer 225 may be a mesh polyurethane ether foam, for example, used in GRANUFOAM™ dressings or VACVERAFLO™ dressings, both of which are available from KCI in San Antonio, Texas.

[0121] The thickness of the fourth layer 225 can also be varied according to the needs of the prescribed therapy. For example, the thickness of the fourth layer 225 can be reduced to alleviate stress on other layers and reduce stretching on surrounding tissues. The thickness of the fourth layer 225 may also affect its compliance. In some embodiments, a thickness in the range of about 2 mm to 10 mm may be suitable. In some embodiments, the fourth layer 225 may be partially or completely opaque, or otherwise designed to block at least a portion of light from passing through.

[0122] exist Figure 2 In an exemplary embodiment, the size and position of the fourth layer 225 can be determined such that the edge of the fourth layer 225 can be placed inside the edge of the third layer 220. For example, the cross-section of the fourth layer 225 can be parallel to the reference plane of the third layer, and the area of ​​said cross-section is smaller than the area of ​​the side surface of the third layer 220. In some embodiments, the fourth layer 225 may have a first side or lower side adapted to be positioned on the third layer 220 and a second side or upper side that can be generally parallel to the first side surface of the fourth layer 225. The first side surface and the second side surface of the fourth layer 225 may each have substantially equal surface areas. The surface areas of the first side surface and the second side surface of the fourth layer 225 may each be smaller than the surface area of ​​the side of the third layer 220 positioned adjacent to the first side surface of the fourth layer 225.

[0123] In some embodiments, a first side of the fourth layer 225 may define a surface 277 having a contact area, which may correspond to a portion of the manifold area of ​​the third layer 220. In some embodiments, the contact area of ​​surface 277 may be less than or smaller than the manifold area of ​​the third layer 220, and also smaller than the area of ​​the other layers of the tissue interface 108. For example, the contact area of ​​the fourth layer 225 may be approximately greater than or equal to 30% of the manifold area of ​​the third layer 220. A portion of the manifold area of ​​the third layer 220, or the manifold edge 278, may not be covered by the fourth layer 225. Thus, in some embodiments, a portion of the upper surface of the third layer 220 may be exposed to or in contact with the cover 106, and may also allow a user to view this portion of the third layer 220 through the cover 106.

[0124] In some embodiments, the manifold area of ​​the third layer 220 and the tissue interface 108 may be defined or correspond to the surface area of ​​the upper or lower side of the third layer 220. For example... Figure 2As shown, the contact area associated with the surface 277 of the fourth layer 225 can be positioned on or adjacent to the central portion of the manifold area of ​​the third layer 220. In such embodiments, the fourth layer 225 can provide enhanced manifolding capability to the central portions(s) of the manifold area(s) of the third layer 220. This enhanced manifolding effect on the central portions(s) of the manifold area(s) of the third layer 220 and the tissue interface 108 can be advantageous because the central portion of the tissue interface 108 can generally align with the tissue site, such as a wound. Furthermore, by including a fourth layer 225 that does not extend to the edges of the manifold area defined by the third layer 220 and therefore by the tissue interface 108, interference between the fourth layer 225 and the edges of the tissue site, such as the area around a wound, can be minimized or avoided.

[0125] exist Figure 2 In some examples, dressing 102 may further include an application device, such as adhesive 280. Adhesive 280 may be, for example, a medically acceptable pressure-sensitive adhesive that extends around, partially or entirely around, the periphery of cover 106. In some embodiments, adhesive 280 may be, for example, an acrylic adhesive having a coating weight between 25 and 65 grams per square meter (gsm). In some embodiments, a thicker adhesive or adhesive combination may be applied to improve sealing and reduce leakage. In some embodiments, such an adhesive 280 layer may be continuous or discontinuous. Discontinuity of adhesive 280 may be provided by holes or pores (not shown) in adhesive 280. Holes or pores in adhesive 280 may be formed after the application of adhesive 280 or formed by patterning adhesive 280 onto a carrier layer, such as the side of cover 106. In some exemplary embodiments, the size of the holes or pores in adhesive 280 may also be determined to enhance the MVTR of dressing 102.

[0126] like Figure 2As shown in the examples, in some embodiments, dressing 102 may include a release liner 285 to protect adhesive 280 before use. Release liner 285 may also provide stiffness to aid, for example, in the deployment of dressing 102. Release liner 285 may be, for example, cast paper, film, or polyethylene. Furthermore, in some embodiments, release liner 285 may be a polyester material, such as polyethylene terephthalate (PET) or a similar polar semicrystalline polymer. The use of a polar semicrystalline polymer in release liner 285 can substantially prevent wrinkling or other deformation of dressing 102. For example, the polar semicrystalline polymer may be highly oriented and resistant to softening, swelling, or other deformation that may occur upon contact with components of dressing 102 or upon exposure to temperature or environmental changes or sterilization. Additionally, a release agent may be disposed on the sides of release liner 285 configured to contact the first layer 205. For example, the release agent may be a silicone coating and may have a release factor suitable for facilitating manual removal of the release liner 285 without damaging or deforming the dressing 102. In some embodiments, the release agent may be a fluorocarbon or a fluorosilicone. In other embodiments, the release liner 285 may be uncoated or otherwise without a release agent.

[0127] Figure 2 An example of the fluid conduction element 290 and the dressing interface 292 is also shown. For example... Figure 2 As shown in the example, the fluid conductor 290 can be a flexible tube, one end of which can be fluidly connected to the dressing interface 292. The dressing interface 292 can be an elbow connector, such as... Figure 2 As illustrated in the example, the elbow connector can be positioned over the hole 294 in the cover 106 to provide a fluid path between the fluid conductor 290 and the tissue interface 108. In some embodiments, the fluid conductor 290 may also include a fluid delivery catheter for use with infusion therapy. Additionally, in some embodiments, the dressing interface 292 may include multiple fluid catheters, such as catheters for transmitting negative pressure and fluid delivery catheters. For example, the dressing interface 292 may be a VACVERAT.RAC™ pad.

[0128] Figure 3 This is a schematic diagram of an instance of the second layer 210, illustrating additional details that can be associated with some embodiments. (As shown in...) Figure 3 As shown in the example, the fluid restriction section 260 can each consist essentially of one or more linear slots having a length of about 3 mm. Figure 3 An example of a uniformly distributed pattern in the fluid confinement section 260 is also shown. Figure 3In this configuration, the fluid restrictors 260 are substantially coaxial with the second layer 210 and are distributed on the second layer 210 in a grid of parallel rows and columns, wherein these slots are also parallel to each other. In some embodiments, the centers of these rows may be spaced approximately 3 mm apart, and the centers of the fluid restrictors 260 within each row may be spaced approximately 3 mm apart, such as... Figure 3 As shown in the example. The fluid restriction sections 260 in adjacent rows can be aligned or offset. For example, as Figure 3 As shown, adjacent rows may be offset such that the fluid restrictors 260 are aligned in alternating rows and spaced approximately 6 mm apart. In some embodiments, the spacing of the fluid restrictors 260 may be varied to increase the density of the fluid restrictors 260 according to treatment needs.

[0129] Figure 4 This is a schematic diagram of an exemplary configuration of hole 240, illustrating additional details that may be associated with some embodiments of the first layer 205. In some embodiments, Figure 4 The hole 240 shown can be associated only with the internal portion 235. Figure 4 In this example, hole 240 is generally circular and has a diameter of approximately 2 millimeters. Figure 4 An example of a uniformly distributed pattern of holes 240 in the internal portion 235 is also shown. Figure 4 In the inner portion 235, holes 240 are distributed in a grid of parallel rows and columns. Within each row and column, the holes 240 can be equidistant from each other, such as... Figure 4 As shown in the examples. Figure 4 An exemplary configuration is shown that can be particularly well-suited for many applications, wherein the holes 240 can be spaced approximately 6 mm apart and offset 3 mm along each row and column.

[0130] Figure 5 yes Figure 4 An exemplary first layer 205 is superimposed on Figure 3 The schematic diagram on the second layer 210 illustrates additional details that can be associated with some exemplary embodiments of the organization interface 108. For example, as Figure 5 As shown, in some embodiments, the fluid restriction portion 260 may be aligned, overlapped, aligned, or otherwise fluidly connected to the aperture 240. In some embodiments, one or more fluid restriction portions of the fluid restriction portion 260 may be aligned with the aperture 240 in the internal portion 235 only, or only partially aligned with the aperture 240. Figure 5In some examples, the fluid restrictors 260 are generally configured such that each fluid restrictor 260 is aligned with only one hole 240. In other examples, one or more fluid restrictors 260 may be aligned with more than one hole 240. For example, any one or more fluid restrictors 260 may be a perforation or window extending across two or more holes 240. Alternatively or concurrently, one or more fluid restrictors 260 may not be aligned with any hole 240.

[0131] As in Figure 5 As illustrated in the examples, the size of the orifice 240 can be determined to expose a portion of the second layer 210, the fluid confinement portion 260, or both, through the first layer 205. In some embodiments, the size of each orifice 240 can be determined to expose no more than two fluid confinement portions 260. In some embodiments, the length of each fluid confinement portion 260 can be substantially equal to or less than the diameter of each orifice 240. In some embodiments, the average size of the fluid confinement portions 260 can be substantially similar to the average size of the orifices 240. For example, in some embodiments, the orifice 240 can be elliptical, and the length of each fluid confinement portion 260 can be substantially equal to its major or minor axis. However, in some embodiments, the size of the fluid confinement portion 260 can exceed the size of the orifice 240, and the size of the orifice 240 can limit the effective size of the fluid confinement portion 260 exposed to the lower surface of the dressing 102.

[0132] Figure 6 This is a perspective view of an instance of layer 220, showing additional details that can be associated with some embodiments. (As in...) Figure 6 As shown in the examples, in some embodiments, the bubbles 270 may be generally hemispherical and uniformly distributed.

[0133] Figure 7 yes Figure 6A cross-sectional view of the third layer 220 illustrates additional details that may be associated with some embodiments. For example, the third layer 220 may be formed of a single fluid-impermeable sheet or membrane of material, which may have bubbles 270 and pores 275 formed thereon. In some embodiments, the third layer 220 may be formed of a polyurethane material. Bubbles 270 may be formed in the third layer 220 by applying a vacuum to the fluid-impermeable membrane of the third layer 220 to create bubbles 270. The size of the bubbles 270 may depend on the specific application of the dressing 102. For example, the height of each bubble 270 may be between approximately 0.5 mm and 3.0 mm, and the diameter may be between approximately 1.0 mm and 3.0 mm. In some embodiments, the height of the bubble 270 may be approximately 1.5 mm, and the diameter may be approximately 1.5 mm. The distance between the individual bubbles 270 may be between approximately 0.5 mm and 3.0 mm, and in some embodiments, the spacing may be approximately 2.0 mm.

[0134] like Figure 7 As shown, holes 275 can be formed in the portion of the third layer 220 located between the bubbles 270 and can extend through the fluid-impermeable material membrane to allow fluid flow through the third layer 220. The number of holes 275 can vary depending on the type of negative pressure and infusion therapy that the therapy system 100 is to provide. Holes 275 can have different shapes, such as circular, elliptical, rectangular, or other irregular shapes. Such holes 275 can have a diameter, major axis, or length between about 0.5 mm and 2.0 mm. In some exemplary embodiments, holes 275 can be formed by cutting or perforating, punching, or cutting the fluid-impermeable material of the third layer 220 using a laser or heat.

[0135] In some embodiments of dressing 102, one or more components of dressing 102 may be additionally treated with an antimicrobial agent. For example, the first layer 205, the second layer 210, the third layer 220, and / or the fourth layer 225 may be coated with an antimicrobial agent. In some embodiments, the second layer 210 may include a polymer coated with or mixed with an antimicrobial agent. In other embodiments, the third layer 220 may include a film coated with or mixed with an antimicrobial agent. In other instances, additionally or alternatively, the cover 106, fluid conduction element 290, dressing interface 292, or other portions of dressing 102 may be treated with one or more antimicrobial agents. Suitable antimicrobial agents may include, for example, metallic silver, PHMB, iodine or complexes and mixtures thereof (such as povidone-iodine), copper compounds, chlorhexidine, or some combination of these materials.

[0136] The various components of dressing 102 can be bonded to each other by solvent-based or non-solvent-based adhesives, or by means such as thermal welding, or otherwise secured to each other without adversely affecting fluid management. Additionally, the second layer 210 or the third layer 220 can be joined to the boundary 255 of the first layer 205 in any suitable manner, such as by welding or adhesive.

[0137] Cover 106, first layer 205, second layer 210, third layer 220, fourth layer 225, or multiple different combinations thereof, can be assembled prior to application or in the field. For example, in some embodiments, cover 106 may be laminated onto fourth layer 225 and / or third layer 220, and second layer 210 may be laminated onto third layer 220, opposite to cover 106. In some embodiments, first layer 205 may also be coupled to second layer 210, opposite to third layer 220. In some embodiments, one or more layers of tissue interface 108 may be co-linear. For example, third layer 220 may be co-linear with second layer 210, such as... Figure 2 As illustrated in the embodiments. In some embodiments, dressing 102 may be provided as a single composite dressing. For example, a first layer 205 may be attached to cover 106 to enclose a second layer 210, a third layer 220, and a fourth layer 225, wherein the first layer 205 is configured to face the tissue site.

[0138] In additional embodiments, dressing 102 may have different combinations of layers and components. For example, tissue interface 108 (e.g., Figure 2 The tissue interface 108 shown can be provided as a standalone product for application to tissue sites. In some other embodiments, the individual layers of the tissue interface 108 and the dressing 102 can be omitted. For example, in some embodiments, the tissue interface 108 may include a second layer 210, a third layer 220, and a fourth layer 225 located between the second layer 210 and the third layer 220. In such embodiments, the third layer 220 may be configured to include a fluid port for mating with a dressing interface, such as dressing interface 292.

[0139] In use, the release liner 285 (if included) can be removed to expose the first layer 205, which can be placed within, above, over, or otherwise close to the tissue site, particularly the surface tissue site and adjacent epidermis. The first layer 205, the second layer 210, and the third layer 220 can be positioned between the fourth layer 225 and the tissue site, which can significantly reduce or eliminate adverse interactions with the fourth layer 225. For example, the first layer 205 can be placed over the surface wound (including the wound edges) and undamaged epidermis to prevent direct contact with the fourth layer 225. Treating a surface wound, or placing the dressing 102 on a surface wound, includes placing the dressing 102 close to the body surface or extending over at least a portion of the body surface. Treating a surface wound does not include placing the dressing 102 entirely within the body or entirely below the body surface, such as placing the dressing in the abdominal cavity. In some applications, the inner portion 235 of the first layer 205 can be positioned adjacent to, close to, or covering the tissue site. In some applications, the second layer 210, the fluid restriction portion 260, or at least some portion thereof, may be exposed to the tissue site through the first layer 205. The periphery 230 of the first layer 205 may be positioned adjacent to or close to tissue surrounding or encircling the tissue site. The first layer 205 may be sufficiently adhesive to hold the dressing 102 in place while allowing the dressing 102 to be removed or repositioned without causing trauma to the tissue site.

[0140] Removing the release liner 285 also exposes the adhesive 280, allowing the cover 106 to be attached to the attachment surface. For example, the cover 106 can be attached to the epidermis surrounding the tissue site around the fourth layer 225, the third layer 220, and the second layer 210. In some embodiments, the adhesive 280 can be in fluid communication with the attachment surface through holes 240 in at least the periphery 230 of the first layer 205. The adhesive 280 can also be in fluid communication with the edge 250 through holes 240 exposed at the edge 250.

[0141] Once the dressing 102 is in the desired position, the adhesive 280 can be pressed through the hole 240 to bond the dressing 102 to the attachment surface. The hole 240 at the edge 250 allows the adhesive 280 to flow around the edge 250 to enhance the adhesion between the edge 250 and the attachment surface.

[0142] In some embodiments, the size of the holes or openings in the first layer 205 can be determined to control the amount of adhesive 280 in fluid communication with the holes 240. For a given geometry of the corner 245, the relative size of the holes 240 can be configured to maximize the surface area of ​​the adhesive 280 exposed at the corner 245 and in fluid communication through the holes 240 at the corner. For example, as Figure 2As shown, these edges 250 may intersect substantially at right angles or approximately 90 degrees to define corners 245. In some embodiments, corners 245 may have a radius of approximately 10 mm. Additionally, in some embodiments, three of the holes 240 having a diameter between approximately 7.75 mm and approximately 8.75 mm may be positioned in a triangular configuration at corners 245 to maximize the exposed surface area of ​​the adhesive 280. In other embodiments, the size and number of holes 240 in corners 245 may be adjusted, if necessary, depending on the selected geometry of corners 245, to maximize the exposed surface area of ​​the adhesive 280. Furthermore, the holes 240 at corners 245 may be completely contained within the first layer 205, significantly preventing lateral fluid communication outside corners 245. The holes 240 at corners 245, completely contained within the first layer 205, significantly prevent fluid communication of the adhesive 280 outside corners 245 and can provide improved manipulation of the dressing during deployment of the dressing 102 at the tissue site. In addition, the essentially adhesive-free exterior of corner 245 can increase the flexibility of corner 245 in order to improve comfort.

[0143] In some embodiments, the adhesive strength of the adhesive 280 can vary at different locations on the dressing 102. For example, the adhesive 280 can have lower adhesive strength in locations adjacent to the first layer 205 (where the holes 240 are relatively large) and higher adhesive strength in locations where the holes 240 are smaller. The combination of the adhesive 280 with lower adhesive strength and the larger holes 240 can provide an adhesion comparable to that of the adhesive 280 with higher adhesive strength at locations where the holes 240 are smaller.

[0144] The geometry and dimensions of the tissue interface 108, the cap 106, or both can be modified to suit a specific application or anatomical structure. For example, the geometry or dimensions of the tissue interface 108 and the cap 106 can be adapted to provide an effective and reliable seal relative to challenging anatomical surfaces at and around the tissue site, such as the elbow or heel. Alternatively or additionally, dimensions can be modified to increase the surface area of ​​the first layer 205, thereby enhancing the movement and proliferation of epithelial cells at the tissue site and reducing the likelihood of inward granulation tissue growth.

[0145] Therefore, in Figure 2In this example, dressing 102 can provide a sealed therapeutic environment that is substantially isolated from the external environment close to the tissue site, and negative pressure source 104 can reduce pressure within the sealed therapeutic environment. First layer 205 can provide an effective and reliable seal relative to challenging anatomical surfaces at and around the tissue site, such as the elbow or heel. Additionally, dressing 102 can allow for reapplication or repositioning to, for example, correct air leaks caused by wrinkles and other discontinuities in dressing 102. In some embodiments, the ability to correct leaks can increase the efficacy of the therapy and reduce power consumption.

[0146] If not already configured, the dressing interface 292 can be positioned above the hole 294 and attached to the cover 106. The fluid conductor 290 can be fluidly connected to the dressing interface 292 and the negative pressure source 104.

[0147] The negative pressure applied through the tissue interface 108 can create a negative pressure differential on the fluid confinement portion 260 in the second layer 210, which can cause the fluid confinement portion 260 to open or expand from its idle state. For example, in some embodiments where the fluid confinement portion 260 may include a substantially closed window through the second layer 210, the pressure gradient on the window can cause strain in the adjacent material of the second layer 210 and increase the size of the window to allow liquid to move through it, similar to the operation of a duckbill valve. Opening the fluid confinement portion 260 allows exudates and other liquids to move through the fluid confinement portion 260, through the orifice 275 of the third layer 220, and into the fourth layer 225 and container 112. Pressure changes can also cause the fourth layer 225 to expand and contract, and the inner boundary 255 of the third layer 220 and the first layer 205 can protect the epidermis from irritation caused by the movement of the fourth layer 225. The third layer 220, the second layer 210, and the first layer 205 can also significantly reduce or prevent tissue exposure to the fourth layer 225, which can inhibit tissue growth into the fourth layer 225.

[0148] In some embodiments, the fourth layer 225 may be hydrophobic to minimize liquid retention or storage in the dressing 102. In other embodiments, the fourth layer 225 may be hydrophilic. In instances where the fourth layer 225 may be hydrophilic, it may also wick fluid from the tissue site while continuing to distribute negative pressure to the tissue site. For example, the wicking properties of the fourth layer 225 may draw fluid from the tissue site via capillary flow or other wicking mechanisms. An example of a hydrophilic fourth layer 225 is a polyvinyl alcohol open-cell foam, such as the VAC WHITEFOAM™ dressing available from Kinetic Concepts, Inc. in San Antonio, Texas. Other hydrophilic foams may include hydrophilic foams made of polyether. Other foams that may exhibit hydrophilic characteristics include hydrophobic foams that have been treated or coated to provide hydrophilicity.

[0149] If the negative pressure source 104 is removed or turned off, the pressure difference on the fluid restriction section 260 can dissipate, thereby allowing the fluid restriction section 260 to move to its idle state and preventing or reducing the rate at which exudate or other fluids can pass through the second layer 210 back to the tissue site.

[0150] In some applications, a filler may also be disposed between the tissue site and the first layer 205. For example, if the tissue site is a surface wound, a wound filler may be applied inside the wound periphery, and the first layer 205 may be disposed around the wound and above the wound filler. In some embodiments, the filler may be a manifold, such as open-cell foam. In some embodiments, the filler may comprise or consist substantially of the same material as the fourth layer 225.

[0151] Alternatively or alternatively, an infusion solution or other fluid may be distributed into the dressing 102, which may increase the pressure in the tissue interface 108. The increased pressure in the tissue interface 108 may create a positive pressure differential on the fluid confinement portion 260 in the second layer 210, which may cause the fluid confinement portion 260 to open or expand from its idle state to allow the infusion solution or other fluid to be distributed to the tissue site.

[0152] Figure 8 This is a schematic diagram of another example of dressing 102. Although Figure 8 Many components of dressing 102 can be used with Figure 2 The dressings 102 are the same or similar, but differences regarding the individual layers of the dressing can be identified. For example, Figure 8 The dressing 102 may include a tissue interface 108 having a fourth layer 225, the shape and / or configuration of which is similar to... Figure 2 The fourth layer, 225, is different. For example... Figure 8As shown, in some embodiments, the fourth layer 225 may be star-shaped or other similar in shape, having a central region 810 and one or more overhangs, such as radial legs 812 or regions, extending from the central region 810. The thickness of the fourth layer 225 may be approximately between 4 mm and 10 mm, and in some embodiments approximately 6 mm. The surface 277 of the fourth layer 225 may define a contact area shaped, defined, or included by the central region 810 and / or one or more overhangs (e.g., radial legs 812). The fourth layer 225 may be placed above or on top of the manifold area of ​​the third layer 220 and may provide enhanced manifolding to the portions of the manifold area of ​​the third layer 220 placed on the contact area defined by the central region 810 and radial legs 812 of the fourth layer 225. The size of the contact area provided by the central region 810 and radial legs 812 of the fourth layer 225 may be based on the dimensions of other layers in the tissue interface 108, such as the third layer 220. In some embodiments, the contact area provided by the fourth layer 225 may be approximately greater than or equal to 30% of the manifold area of ​​the third layer 220.

[0153] Such as about Figure 2 The perimeter of the third layer 220 may define the boundary of the manifold area of ​​the tissue interface 108. In some embodiments, the radial legs 812 of the fourth layer 225 may extend substantially to the edge of the third layer 220 and the boundary of the manifold area. For example, the radial legs 812 of the fourth layer 225 may extend approximately 90% of the length and / or width of the manifold area of ​​the third layer 220. In other words, in some embodiments, approximately 10% of the length and / or width dimension of the manifold area of ​​the third layer 220 may be included beyond the extended area of ​​the radial legs 812. The portion of the third layer 220 within the manifold area may not lie on or be covered by a portion of the contact area of ​​the fourth layer 225, and thus the upper portion of the third layer 220 within the manifold area may be exposed to the cover 106 of the dressing 102. The portion of the third layer 220 not covered by the central region 810 of the fourth layer 225 or the radial legs 812 may remain visible to the user when the user looks at the dressing 102. Additionally, since in some embodiments of the tissue interface 108, the third layer 220, the second layer 210, and the first layer 205 may each include one or more transparent materials, one or more portions of the tissue site may remain visible to the user throughout the entire duration of the dressing 102. Figure 8 The shape and configuration of the fourth layer 225 allow for enhanced visibility of tissue sites through the manifold area between the radial legs 812 of the third layer 220. Figure 8The fourth layer 225 also ensures that the dressing 102 continues to provide improved manifolding capability to all portions of the manifold area that can be aligned with the tissue site (including the outer edge of the manifold area that can correspond to the area around the wound below the tissue site).

[0154] Figure 9 This is a schematic diagram illustrating a dressing 102 according to an additional exemplary embodiment. The tissue interface 108 of the dressing 102 may include a fourth layer 225, which is 'X' shaped or otherwise similarly shaped, having a central region 910 and overhangs (e.g., radial legs 912) extending from the central region 910. The fourth layer 225 may be placed above or on top of the manifold area of ​​the third layer 220 and may provide enhanced manifolding effect on these portions of the manifold area of ​​the third layer 220 placed on the contact area defined by the central region 810 and radial legs 812 of the fourth layer 225. The perimeter of the third layer 220 of the tissue interface 108 may define the boundary of the manifold area of ​​the tissue interface 108.

[0155] and Figure 8 Compared to the fourth layer 225, Figure 9 The fourth layer 225 may include a larger, but possibly smaller, overhang, such as a radial leg 912, extending from the central region 910. In some embodiments, the radial leg 912 is shorter than [the length of the previous layer]. Figure 8 The length of the radial legs 812 is such that the radial legs 912 do not extend so far toward the outer edge of the manifold area of ​​the third layer 220. However, in some embodiments, the width of each radial leg 912 may be greater than that of the other radial legs 812. Figure 8 The width of the radial legs 812. For example, the width of each radial leg 912 can be greater than... Figure 8 The width of each radial leg 812 is approximately 25%-50% larger. Additionally, Figure 9 The thickness of the fourth layer, 225, can be greater than Figure 8 The fourth layer has a thickness of 225. For example, Figure 9 The thickness of the fourth 225 layer can be approximately between 4 mm and 10 mm. Therefore, Figure 9The fourth layer 225 can also provide enhanced manifolding to the portion of the manifold area of ​​the third layer 220 that is placed on or covered by a portion of the contact area of ​​the 'X'-shaped fourth layer 225. The portions of the third layer 220 that are not covered by or placed on the fourth layer 225, or those portions of the third layer 220 outside the contact area of ​​the fourth layer 225, can be exposed to the improvement 106 of the dressing 102 and thus remain visible to the user. The configuration of the 'X'-shaped fourth layer 225 can provide improved visibility through the following layers of the tissue interface 108: these layers correspond to portions of the manifold area of ​​the third layer 220 that are not associated with the fourth layer 225, including the manifold edge 278 around the perimeter of the manifold area and some internal portions of the manifold area between the radial legs 912. Figure 9 The fourth layer 225 can provide a high level of manifolding for both the internal and external areas of the manifold area of ​​the third layer 220. Figure 9 The 'X'-shaped fourth layer 225 allows for good visibility of the manifold edge 278 through the third layer 220, as well as good flexibility of the manifold edge 278 of the third layer 220. The manifold edge 278 can be aligned with this portion of the tissue interface 108 for placement or application to the wound periphery of the tissue site. Therefore, both the enhanced visibility through the tissue interface 108 and the good flexibility of the tissue interface can be particularly advantageous during dressing application 102, when the user can attempt to align the edge of the manifold area with a portion of the wound periphery.

[0156] Figure 10 This is a schematic diagram showing another example of dressing 102. Although Figure 10 The components of dressing 102 can be used with Figure 2 The dressing is the same as or similar to 102, but Figure 10 The arrangement and / or order of the layers of dressing 102 may differ. For example, Figure 10 The various layers of the organizational interface 108 can be different Figure 2 The organization interface 108 is arranged or stacked according to the order of its layers. More specifically, in some embodiments, instead of placing the fourth layer 225 on top of the third layer 220, or between the third layer 220 and the cover 106, it can be arranged or stacked according to the order of its layers. Figure 10 The fourth layer 225 is placed below or beneath the third layer 220. Therefore, in Figure 10 In an exemplary embodiment, the organization interface 108 may include a fourth layer 225 located between the second layer 210 and the third layer 220. For example... Figure 10 As shown, the third layer 220 can be oriented such that the bubble 270 protrudes downward and contacts the fourth layer 225. In other embodiments, the orientation of the third layer 220 can also be reversed. Figure 10As shown, the fourth layer 225 can have a similar Figure 2 The fourth layer is a square shape of 225, but... Figure 10 The fourth layer 225 can also have different shapes or configurations, such as Figure 8 and Figure 9 The corresponding star-shaped or X-shaped configuration. Figure 10 The fourth layer 225 can enhance manifolding by relating the manifold area of ​​the third layer 220 to the contact area defined by the surface 277 of the fourth layer 225. The fourth layer 225 can also provide good visibility of the tissue site through the tissue interface 108 and the dressing 102 because the contact area of ​​the fourth layer 225 can be smaller than the manifold areas of the third layer 220, the second layer 210, and the first layer 205, all of which can be at least partially transparent.

[0157] In some additional or alternative embodiments, the fourth layer 225 may include a foam material that allows additional visibility through the tissue interface 108. For example, the fourth layer 225 may be formed from a coarse, rigid mesh foam (e.g., a mesh foam with 2 pores per inch (ppi) to 3 ppi and a pore size between about 2 mm and 10 mm). In some embodiments, the foam of the fourth layer 225 may be Z3SA material available from FXI, Pennsylvania, USA. Alternatively, the foam of the fourth layer 225 may be made from a pigment-free polymer, such as polyurethane, which can provide additional translucency. In some additional embodiments, the fourth layer 225 may include a portion of coarser foam (e.g., 2 ppi to 10 ppi foam) laminated onto a portion of a perforated 45 ppi foam (e.g., the foam more typically included in other disclosed embodiments of the fourth layer 225 of the tissue interface 108). In some cases, the fourth layer 225 may have a reduced material content, which may allow for better delivery of possible infusion treatment fluids to the underlying wound and surrounding area, as well as produce a higher fluid shear or cleansing effect on tissue interfaces.

[0158] In some other embodiments, additional features may be suitable for the fourth layer 225. For example, instead of a foam material, the fourth layer 225 may be in the form of a nonwoven fabric perforated with pores having diameters between approximately 5 mm and 10 mm. In other cases, the foam of the fourth layer 225 may be replaced by a three-dimensional spaced textile, wherein a perforated structure has been woven into the upper and lower surfaces of the textile. In some other embodiments, the fourth layer 225 may comprise a felted perforated foam. In yet another embodiment, the fourth layer 225 may be formed of foam with large perforations, and the perforations may have a variety of different shapes, such as circular, biconvex lens-shaped, polygonal, and other shapes. In some cases, the larger perforations of the foam may allow the fourth layer 225 to better handle thick or highly viscous wound exudates.

[0159] In yet another embodiment, the fourth layer 225 may be formed of an imprinted perforated membrane (e.g., a membrane with bubbles similar to those in the third layer 220) instead of foam material. The imprinted perforated membrane can provide improved transparency. In additional embodiments, the fourth layer 225 may comprise one or more layers of molded mesh or porous membrane (with pore sizes ranging from approximately 2 mm to 10 mm in diameter), such as materials available from DelStar Technologies, Inc., Middletown, Delaware, USA. In some cases, reducing the amount of foam material or using alternative materials instead of foam for the fourth layer 225 can provide increased flexibility to the tissue interface 108. Increased flexibility allows the tissue interface 108 to better conform to and seal to traditionally challenging wound locations (e.g., joints, feet, hands, amputation sites, and bone anatomy).

[0160] In some embodiments of the organization interface 108, additional features may also be included. For example, to further assist the organization interface, a radial arm that may be located in the fourth layer 225 (e.g., Figure 8 and Figure 9 The manifolding effect in the area between the corresponding radial legs 812 or 912 in the embodiments can imprint multiple portions of the second layer 210. In some cases, the second layer 210 can be imprinted on a surface opposite to the tissue site to maintain a smooth surface of the second layer 210 facing the wound or surrounding wound area of ​​the tissue site. Examples of imprint films suitable for use as the second layer 210 are available from Charter Nex Corporation, Wisconsin, USA. Additionally, some embodiments of the fourth layer 225 may have radial arms formed of a mesh foam, woven or nonwoven material, or bubble material with interconnected portions like a web.

[0161] A method for treating a surface wound to promote healing and granulation tissue growth may include applying a dressing 102 to the surface wound and sealing the dressing 102 to the epidermis adjacent to the surface wound. For example, a first layer 205 may be placed on the surface wound to cover at least a portion of the edge of the surface wound and the area surrounding the wound adjacent to the surface wound. A cover 106 may also be attached to the epidermis around the first layer 205. The dressing 102 may be fluidly coupled to a negative pressure source, such as a negative pressure source 104. Negative pressure from the negative pressure source 104 may be applied to the dressing 102 to open a fluid restriction 260. The fluid restriction 260 may be closed by blocking, stopping, or reducing the negative pressure. The third layer 220, the second layer 210, and the first layer 205 may significantly prevent tissue in the surface wound from being exposed to the fourth layer 225, thereby inhibiting tissue growth into the fourth layer 225. The dressing 102 may also significantly prevent the area around the wound from becoming swollen.

[0162] In an additional embodiment, a method for treating a surface wound may include applying a dressing 102 to the surface wound and sealing the dressing 102 to the epidermis adjacent to the surface wound. The dressing 102 may include: a lower layer comprising a first at least partially transparent, liquid-impermeable material membrane having a plurality of fluid-restricting portions to allow fluid from the wound site to pass through the lower layer. The dressing 102 may further include an upper layer positioned above the lower layer, wherein the upper layer comprises a second transparent material membrane and further includes a fluid port for cooperating with a negative pressure source. Additionally, the dressing 102 may include an intermediate layer between the lower and upper layers. The intermediate layer may include a foam, and the area of ​​the foam may be smaller than the area of ​​the lower layer to allow visibility of the surface wound beneath the upper and lower layers. The dressing 102 may further include a third membrane coupled to the lower layer and opposite to the upper layer, wherein the third membrane comprises a hydrophobic material having a plurality of pores. In some embodiments, the hydrophobic material may be silicone.

[0163] The systems, devices, and methods described herein can offer significant advantages over existing dressings. For example, some dressings used in negative pressure therapy may require considerable time and skill to properly determine their size and apply to achieve good fit and seal. In contrast, dressing 102 can be applied simply, reducing application and removal time. In some embodiments, dressing 102 can be a fully integrated negative pressure therapy dressing that can be applied in one step to tissue sites, including around wounds, without needing to be cut to a fixed size, while still providing or improving many of the benefits of other negative pressure therapy dressings that require size adjustment. Such benefits can include good manifolding, beneficial granulation, protection of surrounding tissue from blistering, and minimally invasive yet highly sealing adhesion. Dressing 102 can also conform to tissue sites and occupy significant space in prominent tissue areas. These features can be particularly beneficial for surface wounds with moderate depth and moderate to high levels of exudate, and therefore can provide significant benefits to tissue sites other than those consisting only of superficial wounds.

[0164] Dressing 102 can also promote granulation tissue growth while reducing the chance of granulation tissue growing inward into the layers of tissue interface 108. For example, by including porous materials within other layers, such as silicone and / or polyethylene, a high level of granulation tissue growth at the tissue site can be achieved while preventing significant inward tissue growth into dressing 102. Additionally, macro-strain can be provided to the edges of the tissue site (e.g., wound edges) while preventing the surrounding wound area from becoming saturated. Therefore, reduced trauma to the tissue site during dressing removal is possible, while also allowing for longer dressing application times. Furthermore, by including layers covering the entire manifold area not spanning other layers of dressing 102, dressing 102 can provide the combined benefits of transparent pressure manifolds for visibility of the tissue site, while also incorporating a foam material optimized for rapid removal of large volumes of fluid for superior pressure manifolding capabilities. Dressing 102 can promote granulation tissue growth while reducing the likelihood of inward tissue growth, and the dressing can be applied for extended periods, such as up to seven days. In addition, caregivers can see the tissue site through the manifold area of ​​the dressing during the extended dressing time without damaging the dressing.

[0165] Another associated advantage of the disclosed dressing is that it eliminates the need for users to resize or cut portions of the foam (e.g., the foam associated with the fourth layer 225) to ensure the foam is positioned inside the wound edge to avoid irritating and / or softening the surrounding tissue. It also eliminates the need to apply a larger protective boundary of the dressing, such as other layers of dressing 102, to the surrounding wound area—sometimes referred to as applying a “windowpane” to the wound peri-wound area—due to concerns about incorrect resizing of the foam granulation layer of dressing 102. For example, the need for users to apply a band of protective material around the boundary of the tissue site can be reduced or eliminated, for example, due to concerns about foam or other manifold contact with and soaking of the wound peri-wound area. Therefore, the disclosed dressing can provide wound filling and / or covering to allow for fluid management and the channeling of negative pressure, without softening the wound edge or requiring resizing. Because the opaque foam manifold component of the disclosed dressing does not extend across the entire manifolded area of ​​the dressing layer(s), the user can see the wound through other layers that are at least partially transparent corresponding to the manifolded area of ​​the dressing, which makes it easier to align the manifolded area of ​​the dressing with the wound. In some embodiments, the disclosed dressing may also provide compression around the wound, thereby reducing edema. Some embodiments of dressing 102 may be retained on the tissue site for at least 5 days, and some embodiments may be retained for at least 7 days. The antimicrobial agent in dressing 102 can extend the usable life of dressing 102 by reducing or eliminating the risk of infection that may be associated with prolonged use, especially for infected or highly exudative wounds. Additionally, some embodiments of dressing 102 can be used with existing systems for providing negative pressure and / or fluid infusion therapy to the tissue site.

[0166] Although illustrated in some exemplary embodiments, those skilled in the art will recognize that the systems, devices, and methods described herein are readily adaptable and subject to various changes and modifications. Furthermore, unless the context clearly requires, the use of terms such as “or” to describe different alternatives need not be mutually exclusive, and unless the context clearly requires, the indefinite articles “a” or “an” do not limit the subject matter to a single instance. Components can also be combined or excluded in various configurations for purposes of sale, manufacture, assembly, or use. For example, in some configurations, dressing 102, container 112, or both may be eliminated or separated from other components for manufacture or sale. In other exemplary configurations, controller 110 may also be manufactured, configured, assembled, or sold independently of other components.

[0167] The appended claims set forth the novelty and inventive step aspects of the subject matter described above; however, the claims may also cover other subject matter not explicitly listed in detail. For example, certain features, elements, or aspects may be omitted from the claims if it is not necessary to distinguish novel and inventive features from those known to a person skilled in the art. The features, elements, and aspects described herein may also be combined or replaced with alternative features for the same, equivalent, or similar purposes without departing from the scope of the invention as defined by the appended claims.

Claims

1. A dressing for treating tissue sites using negative pressure, said dressing comprising: Non-porous material film layer; Multiple fluid confinement sections passing through the membrane layer; A first manifold layer adjacent to the membrane layer, the first manifold layer comprising a transparent material; Configured to allow fluid to pass through the orifice of the first manifold layer; as well as A second manifold layer adjacent to the first manifold layer, the second manifold layer comprising foam; In this embodiment, at least a portion of the transparent material is exposed outside one or more perimeter edges of the foam.

2. The dressing as claimed in claim 1, wherein: The first manifold layer has a periphery that defines the manifold area; The foam is a cylinder, and the cylinder has a surface that defines the surface area; and The surface area of ​​the foam is smaller than the area of ​​the manifold.

3. The dressing as claimed in claim 1, wherein, The foam includes radial legs.

4. The dressing as claimed in claim 1, wherein, The foam comprises at least three radial legs.

5. The dressing as claimed in claim 1, wherein, The foam comprises at least four radial legs.

6. The dressing as claimed in claim 1, wherein, The foam has a star shape.

7. The dressing as claimed in claim 1, wherein, When viewed from the top of the dressing, the portion of the transparent material is exposed around the foam.

8. A dressing for treating tissue sites using negative pressure, said dressing comprising: Fluid control layer; A first manifold layer adjacent to the fluid control layer, the first manifold layer being configured to allow at least a portion of the tissue site to be seen through the first manifold layer; as well as A second manifold layer connected to the first manifold layer; The first manifold layer is visible around the second manifold layer.

9. A dressing for treating tissue sites using negative pressure, said dressing comprising: The lower layer includes a first membrane of at least partially transparent liquid-impermeable material having a first side and a second side, and further includes a plurality of fluid confinement portions to allow fluid from the tissue site to pass through the lower layer; An upper layer positioned above the lower layer, the upper layer comprising: A second transparent material film, the upper layer further including a fluid port for cooperating with a negative pressure source; and An intermediate layer located between the lower layer and the upper layer, the intermediate layer comprising foam, wherein the surface area of ​​the foam face is smaller than the surface area of ​​the second side face of the first membrane of the lower layer, so as to allow visibility of the tissue sites beneath the upper and lower layers.

10. The dressing as claimed in claim 9, wherein, The second membrane includes protrusions.

11. The dressing as claimed in claim 9, wherein, The second membrane includes spacers, wherein each spacer has a height of about 0.5 mm to about 2 mm.

12. The dressing as claimed in claim 9, wherein, The surface area of ​​the foam is less than 50% of the surface area of ​​the second side of the first film in the lower layer.

13. The dressing as claimed in claim 9, wherein, The upper layer extends beyond the perimeter of the lower layer.

14. The dressing as claimed in claim 9, wherein, The upper layer further includes an adhesive applied to a first surface of the upper layer.

15. The dressing of claim 9, further comprising a third membrane attached to the lower layer and opposite to the upper layer, the third membrane comprising a hydrophobic material having a plurality of pores.

16. The dressing as claimed in claim 15, wherein, The hydrophobic material is a gel.

17. The dressing as claimed in claim 15, wherein, The hydrophobic material includes silicone.

18. A dressing for treating tissue sites using negative pressure, said dressing comprising: The first membrane includes non-porous materials; A second membrane adjacent to the first membrane, the second membrane comprising: A transparent material having a first side and a second side, wherein the first side and the second side each have a surface area, and Configured to allow fluid to pass through the pores in the transparent material; and A manifold layer adjacent to the second side surface of the second membrane, the manifold layer comprising foam having a surface area defined by the foam, the surface area being smaller than the surface area of ​​the second side surface of the second membrane.

19. A dressing for treating tissue sites using negative pressure, said dressing comprising: A first membrane, the first membrane comprising a non-porous material and a plurality of fluid confinement portions; A second membrane adjacent to the first membrane, the second membrane comprising: Transparent materials with raised structures, and Configured to allow fluid to pass through the pores in the transparent material; and A manifold layer adjacent to the second membrane, the manifold layer comprising foam; The foam has a cross-section parallel to the second membrane, and the area of ​​the cross-section is smaller than the area of ​​the side surface of the second membrane.

20. A dressing for treating tissue sites using negative pressure, said dressing comprising: The first layer comprises a first non-porous material and has a first side surface and a second side surface; A second layer adjacent to a second side of the first layer, the second layer comprising a transparent material having a first side and a second side, and further comprising a hole configured to allow fluid to pass through the second layer; as well as A third layer having a first side and a second side parallel to the first side, wherein the first side of the third layer is positioned adjacent to the second side of the second layer, and the surface areas of the first side and the second side of the third layer are each smaller than the surface area of ​​the second side of the second layer. The third layer includes foam.